Protocol for the development of a consensus practice guideline To address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy

Tyler J. Varisco,Hannah Fish,Joshua Bolin,David Dadiomov,Lucas G. Hill,Ekere J. Essien,Matthew A. Wanat,Diane Ginsburg,Jeanne Waggener,Sahar Yazdanfard,Juhyeon Song,Whanhui Chi,Douglas Thornton
DOI: https://doi.org/10.1186/s13690-024-01287-4
2024-04-27
Archives of Public Health
Abstract:Less than half of community pharmacies in the United States stock buprenorphine products indicated for the treatment of opioid use disorder. This lack of access to buprenorphine in community pharmacies is a significant barrier to care. To address this issue, this protocol outlines a comprehensive approach to develop a practice guideline aimed at improving access to safe and effective opioid use disorder treatment in community pharmacies.
public, environmental & occupational health
What problem does this paper attempt to address?